HRP20170622T1 - Derivati piridinila i kondenziranog piridinil triazolona - Google Patents

Derivati piridinila i kondenziranog piridinil triazolona Download PDF

Info

Publication number
HRP20170622T1
HRP20170622T1 HRP20170622TT HRP20170622T HRP20170622T1 HR P20170622 T1 HRP20170622 T1 HR P20170622T1 HR P20170622T T HRP20170622T T HR P20170622TT HR P20170622 T HRP20170622 T HR P20170622T HR P20170622 T1 HRP20170622 T1 HR P20170622T1
Authority
HR
Croatia
Prior art keywords
triazol
tautomer
acryloylpyrrolidin
compound
oxy
Prior art date
Application number
HRP20170622TT
Other languages
English (en)
Inventor
John David Lawson
Mark Sabat
Nicholas Scorah
Christopher Smith
Phong H. Vu
Haixia Wang
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HRP20170622T1 publication Critical patent/HRP20170622T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (26)

1. Spoj s formulom 1, [image] njegov tautomer ili farmaceutski prihvatljiva sol spoja ili tautomer, pri čemu: R1 je odabran od vodika, halo, -CN, C1-4 alkila, C1-4 haloalkila, i -OR14; R2 i R3 su svaki neovisno odabrani od vodika, halo, -CN, R6, i R7, ili R2 i R3, zajedno s ugljikovim atomima na koje su oni vezani, tvore benzenski prsten ili piridinski prsten u kojem je benzenski prsten proizvoljno supstituiran s jednim do četiri supstituenta koji su neovisno odabrani od halo, -CN, R6, i R7, i piridinski prsten je proizvoljno supstituiran s jednim do tri supstituenta koji su neovisno odabrani od halo, -CN, R6, i R7; R4 ima formulu [image] u kojoj označava točku vezanja; L je odabran od -O-, -CH2O-, i -N(R4e)-; R4a je odabran od -CH2R5 i etenila proizvoljno supstituiranog s jednim do tri supstituenta koji su neovisno odabrani od halo, cijano, i R7; i (a) R4c je vodik, R4e je odabran od vodika i C1-4 alkila kada L je -N(R4e)-, i R4b i R4d, zajedno s dušikovim atomom i ugljikovim atomima na koje su R4b, R4c, i R4d odgovarajuće vezani, tvore pirolidinski prsten ili piperidinski prsten, svaki prsten je proizvoljno supstituiran s jednim do šest supstituenata koji su neovisno odabrani iz niza koji čine halo, C1-4 alkil, i C1-4 haloalkil; ili (b) R4b je odabran od vodika i C1-4 alkila, R4d je vodik, L je -N(R4e)-, i R4c i R4e, zajedno s ugljikovim atomima i dušikovim atomom na koje su R4c, R4d, i R4e odgovarajuće vezani, tvore pirolidinski prsten ili piperidinski prsten, svaki prsten je proizvoljno supstituiran s jednim do šest supstituenata koji su neovisno odabrani od halo, C1-4 alkila, i C1-4 haloalkila; ili (c) R4d je vodik, R4e je odabran od vodika i C1-4 alkila kada L je -N(R4e)-, i R4b i R4c, zajedno s dušikovim atomom i ugljikovim atomima na koje su R4b i R4c odgovarajuće vezani, tvore pirolidinski prsten ili piperidinski prsten, svaki prsten je proizvoljno supstituiran s jednim do šest supstituenata koji su neovisno odabrani od halo, C1-4 alkila, i C1-4 haloalkila; R5 je odabran od vodika, halo, i C1-4 alkila; svaki R6 je neovisno odabran od -OR8, -N(R8)R9, -NR8C(O)R9, -NHC(O)NR8R9, -NR8C(O)NHR9, -C(O)R8, -C(O)OR8, -C(O)N(R8)R9, -C(O)N(R8)OR9, -C(O)N(R8)S(O)2R7, -N(R8)S(O)2R7, -SR8, -S(O)R7, -S(O)2R7, i -S(O)2N(R8)R9; svaki R7 je neovisno odabran od (a) C1-6 alkila, C2-6 alkenila, i C2-6 alkinila, svaki proizvoljno supstituiran s jednim do pet supstituenata koji su neovisno odabrani od halo, okso, -CN, i R10; i (b) C3-10 cikloalkil-(CH2)m-, C6-14 aril-(CH2)m-, C2-6 heterociklil-(CH2)m-, i C1-9 heteroaril-(CH2)m-, svaki proizvoljno supstituiran s jednim do pet supstituenata koji su neovisno odabrani iz niza koji čine halo, okso, -CN, R10, i C1-6 alkil proizvoljno supstituiran s jednim do pet supstituenata koji su neovisno odabrani od halo, okso, -CN, i R10; svaki R8 i R9 je neovisno odabran od (a) vodika; (b) C1-6 alkila, C2-6 alkenila, i C2-6 alkinila, svaki proizvoljno supstituiran s jednim do pet supstituenata koji su neovisno odabrani od halo, okso, -CN, i R10; i (c) C3-10 cikloalkil-(CH2)m-, C6-14 aril-(CH2)m-, C2-6 heterociklil-(CH2)m-, i C1-9 heteroaril-(CH2)m-, svaki proizvoljno supstituiran s jednim do pet supstituenata koji su neovisno odabrani iz niza koji čine halo, okso, -CN, R10, i C1-6 alkil proizvoljno supstituiran s jednim do pet supstituenata koji su neovisno odabrani od halo, okso, -CN, i R10; svaki R10 je neovisno odabran od -OR11, -N(R11)R12, -N(R11)C(O)R12, -NHC(O)NR11R12, -NR11C(O)NHR12, -C(O)R11, -C(O)OR11, -C(O)N(R11)R12, -C(O)N(R11)OR12, -C(O)N(R11)S(O)2R13, -NR11S(O)2R13, -SR11, -S(O)R13, -S(O)2R13, i -S(O)2N(R11)R12; svaki R11 i R12 je neovisno odabran od (a) vodika; i (b) C1-6 alkila i C3-10 cikloalkil-(CH2)m-, svaki je proizvoljno supstituiran s od jednog do pet supstituenata koji su neovisno odabrani od halo, okso, -CN, -OH, i -NH2; svaki R13 je neovisno odabran od C1-6 alkila i C3-10 cikloalkil-(CH2)m-, svaki je proizvoljno supstituiran s od jednog do pet supstituenata koji su neovisno odabrani od halo, okso, -CN, -OH, i -NH2; svaki R14 je neovisno odabran od vodika, C1-4 alkila, i C1-4 haloalkila; i svaki m je neovisno odabran od 0, 1, 2, 3, i 4; pri čemu svaki heteroaril i heterociklil od R7, R8, i R9 neovisno ima jedan do četiri heteroatoma, svaki od heteroatoma je neovisno odabran od N, O, i S.
2. Spoj, tautomer ili farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da R1 je vodik.
3. Spoj, tautomer ili farmaceutski prihvatljiva sol prema bilo kojem od prethodnih zahtjeva, naznačen time da R2 i R3, zajedno s ugljikovim atomima na koje su oni vezani, tvore benzenski prsten ili piridinski prsten u kojem je benzenski prsten proizvoljno supstituiran s jednim do četiri supstituenta koji su neovisno odabrani od halo, -CN, R6, i R7, i piridinski prsten je proizvoljno supstituiran s jednim do tri supstituenta koji su neovisno odabrani od halo, -CN, R6, i R7.
4. Spoj, tautomer ili farmaceutski prihvatljiva sol prema bilo kojem od prethodnih zahtjeva, naznačen time da R4a je nesupstituirani etenil.
5. Spoj, tautomer ili farmaceutski prihvatljiva sol prema bilo kojem od prethodnih zahtjeva, naznačen time da R4c je vodik, R4e je odabran od vodika i C1-4 alkila kada L je -N(R4e)-, i R4b i R4d, zajedno s dušikovim atomom i ugljikovim atomima na koje su R4b, R4c, i R4d odgovarajuće vezani, tvore pirolidinski prsten ili piperidinski prsten, svaki prsten je proizvoljno supstituiran s od jednog do šest supstituenata koji su neovisno odabrani od halo, C1-4 alkila, i C1-4 haloalkila.
6. Spoj, tautomer ili farmaceutski prihvatljiva sol prema zahtjevu 5, naznačen time da R4b i R4d, zajedno s dušikovim atomom i ugljikovim atomima na koje su R4b, R4c, i R4d odgovarajuće vezani, tvore pirolidinski prsten koji je proizvoljno supstituiran s od jednog da četiri supstituenta koji su neovisno odabrani od halo, C1-4 alkila, i C1-4 haloalkila.
7. Spoj, tautomer ili farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 5-6, naznačen time da prsten koji tvore R4b i R4d, zajedno s dušikovim atomom i ugljikovim atomima na koje su R4b, R4c, i R4d odgovarajuće vezani, je nesupstituiran.
8. Spoj, tautomer ili farmaceutski prihvatljiva sol prema bilo kojem od prethodnih zahtjeva, naznačen time da L je -N(R4e)-.
9. Spoj, tautomer ili farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1-7, naznačen time da L je -O-.
10. Spoj prema zahtjevu 1, naznačen time da je odabran od slijedećih spojeva: (R)-3-(1-((1-metakriloilpirolidin-3-il)oksi)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (R)-3-(1-((1-akriloilpirolidin-3-il)oksi)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (R,E)-3-(1-((1-(but-2-enoil)pirolidin-3-il)oksi)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; N-(1-(3-(5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il)izokinolin-1-il)pirolidin-3-il)akrilamide; (S)-3-(1-((1-akriloilpirolidin-3-il)oksi)izokinolin-3-il)-1H-1,2,4-triazol-5(4H-on; (S)-3-(1-(((1-akriloilpirolidin-2-il)metil)amino)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-2-il)metoksi)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-3-il)amino)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (R)-3-(1-((1-akriloilpirolidin-2-il)metoksi)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-metakriloilpirolidin-3-il)amino)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-3-il)(metil)amino)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-metakriloilpirolidin-3-il)oksi)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-(((1-akriloilpirolidin-3-il)oksi)metil)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S,E)-5-(1-((1-(4-(dimetilamino)but-2-enoil)pirolidin-3-il)oksi)izokinolin-3-il)-2,4-dihidro-3H-1,2,4-triazol-3-on; (S,E)-3-(1-((1-(but-2-enoil)pirolidin-3-il)amino)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(8-((1-akriloilpirolidin-3-il)oksi)-1,7-naftiridin-6-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(8-((1-akriloilpirolidin-3-il)amino)-1,7-naftiridin-6-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-3-il)oksi)-7-fluoroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; 3-(1-((trans-1-akriloil-4-metilpirolidin-3-il)oksi)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; 3-(1-(((3R,4S)-1-akriloil-4-metilpirolidin-3-il)oksi)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; 3-(1-(((3S,4R)-1-akriloil-4-metilpirolidin-3-il)oksi)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-3-il)oksi)-8-fluoroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-3-il)amino)-8-fluoroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-3-il)oksi)-7-kloroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-3-il)amino)-7-fluoroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-3-il)amino)-7-kloroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-3-il)oksi)-8-kloroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-3-il)amino)-8-kloroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((1-akriloilpirolidin-3-il)amino)-8-metoksiizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(6-((1-akriloilpirolidin-3-il)oksi)-4-metilpiridin-2-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(6-((1-akriloilpirolidin-3-il)oksi)piridin-2-il)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(6-((1-akriloilpirolidin-3-il)oksi)-5-metilpiridin-2-il)-1H-1,2,4-triazol-5(4H)-on; (S)-5-(1-((1-(2-kloroacetil)pirolidin-3-il)oksi)izokinolin-3-il)-2,4-dihidro-3H-1,2,4-triazol-3-on; (S)-5-(1-((1-(2-kloroacetil)pirolidin-3-il)amino)izokinolin-3-il)-2,4-dihidro-3H-1,2,4-triazol-3-on; (S)-5-(1-((1-akriloilpiperidin-3-il)oksi)izokinolin-3-il)-2,4-dihidro-3H-1,2,4-triazol-3-on; (S)-5-(1-((1-acetilpirolidin-3-il)oksi)izokinolin-3-il)-2,4-dihidro-3H-1,2,4-triazol-3-on; (S)-5-(1-((1-propionilpirolidin-3-il)oksi)izokinolin-3-il)-2,4-dihidro-3H-1,2,4-triazol-3-on; tautomer bilo kojeg od gore navedenih spojeva; stereoizomer bilo kojeg od gore navedenih spojeva ili tautomera; i farmaceutski prihvatljiva sol bilo kojeg od gore navedenih spojeva, tautomera ili stereoizomera.
11. Spoj prema zahtjevu 1, naznačen time da je (S)-3-(1-((1-akriloilpirolidin-3-il)oksi)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on, njegov tautomer, ili farmaceutski prihvatljiva sol spoja ili tautomer.
12. Spoj prema zahtjevu 1, naznačen time da je (S)-3-(1-((1-akriloilpirolidin-3-il)amino)izokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on, njegov tautomer, ili farmaceutski prihvatljiva sol spoja ili tautomer.
13. Spoj prema zahtjevu 1, naznačen time da je (S)-3-(8-((1-akriloilpirolidin-3-il)oksi)-1,7-naftiridin-6-il)-1H-1,2,4-triazol-5(4H)-on, njegov tautomer, ili farmaceutski prihvatljiva sol spoja ili tautomer.
14. Spoj prema zahtjevu 1, naznačen time da je (S)-3-(8-((1-akriloilpirolidin-3-il)amino)-1,7-naftiridin-6-il)-1H-1,2,4-triazol-5(4H)-on, njegov tautomer, ili farmaceutski prihvatljiva sol spoja ili tautomer.
15. Spoj prema zahtjevu 1, naznačen time da je (S)-3-(1-((1-akriloilpirolidin-3-il)oksi)-8-fluoroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on, njegov tautomer, ili farmaceutski prihvatljiva sol spoja ili tautomer.
16. Spoj prema zahtjevu 1, naznačen time da je (S)-3-(1-((1-akriloilpirolidin-3-il)amino)-8-fluoroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on, njegov tautomer, ili farmaceutski prihvatljiva sol spoja ili tautomer.
17. Spoj prema zahtjevu 1, naznačen time da je (S)-3-(1-((1-akriloilpirolidin-3-il)oksi)-7-kloroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on, njegov tautomer, ili farmaceutski prihvatljiva sol spoja ili tautomer.
18. Spoj prema zahtjevu 1, naznačen time da je (S)-3-(1-((1-akriloilpirolidin-3-il)amino)-7-kloroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on, njegov tautomer, ili farmaceutski prihvatljiva sol spoja ili tautomer.
19. Spoj prema zahtjevu 1, naznačen time da je (S)-3-(1-((1-akriloilpirolidin-3-il)oksi)-8-kloroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on, njegov tautomer, ili farmaceutski prihvatljiva sol spoja ili tautomer.
20. Spoj prema zahtjevu 1, naznačen time da je (S)-3-(1-((1-akriloilpirolidin-3-il)amino)-8-kloroizokinolin-3-il)-1H-1,2,4-triazol-5(4H)-on, njegov tautomer, ili farmaceutski prihvatljiva sol spoja ili tautomer.
21. Farmaceutski pripravak naznačen time da sadrži: spoj, tautomer ili farmaceutski prihvatljivu sol kako je definirano u bilo kojem od zahtjeva 1-20; i farmaceutski prihvatljivo pomoćno sredstvo.
22. Spoj, tautomer ili farmaceutski prihvatljiva sol kako je definirano u bilo kojem od zahtjeva 1-20, naznačen time da je za uporabu kao lijek.
23. Spoj, tautomer ili farmaceutski prihvatljiva sol kako je definirano u bilo kojem od zahtjeva 1-20, naznačen time da je za uporabu za liječenje bolesti, poremećaja ili stanja koje je odabrano od reakcija preosjetljivosti tip I, autoimunih bolesti, upalnih bolesti, raka, te ne-malignih proliferativnih poremećaja.
24. Spoj, tautomer ili farmaceutski prihvatljiva sol kako je definirano u bilo kojem od zahtjeva 1-20, naznačen time da je za uporabu za liječenje bolesti, poremećaja ili stanja koje je odabrano iz skupa koji čine alergijski rinitis, astma, atopijski dermatitis, reumatoidni artritis, multipla skleroza, sistemski eritematozni lupus, lupus nefritis, psorijaza, imunološka trombocitopenična purpura, upalna bolest crijeva, kronična opstruktivna plućna bolest, Sjogrenov sindrom, ankilozirajući spondilitis, Behcetova bolest, bolest presatka protiv domaćina, pemfigus vulgaris, idiopatska plazmocitna limfadenopatija, ateroskleroza, infarkt miokarda, i tromboza.
25. Spoj, tautomer ili farmaceutski prihvatljiva sol kako je definirano u bilo kojem od zahtjeva 1-20, naznačen time da je za uporabu za liječenje bolesti, poremećaja ili stanja koje je odabrano od limfoma B-stanica, kronične limfocitne leukemije, i multiplog mijeloma.
26. Kombinacija djelotvorne količine spoja, tautomera ili farmaceutski prihvatljive soli kako je definirano u bilo kojem od zahtjeva 1-20, i barem jednog dodatnog farmakološki aktivnog sredstva.
HRP20170622TT 2013-03-11 2017-04-20 Derivati piridinila i kondenziranog piridinil triazolona HRP20170622T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361776445P 2013-03-11 2013-03-11
PCT/US2014/022801 WO2014164558A1 (en) 2013-03-11 2014-03-10 Pyridinyl and fused pyridinyl triazolone derivatives
EP14719130.8A EP2970202B1 (en) 2013-03-11 2014-03-10 Pyridinyl and fused pyridinyl triazolone derivatives

Publications (1)

Publication Number Publication Date
HRP20170622T1 true HRP20170622T1 (hr) 2017-06-30

Family

ID=50543655

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170622TT HRP20170622T1 (hr) 2013-03-11 2017-04-20 Derivati piridinila i kondenziranog piridinil triazolona

Country Status (42)

Country Link
US (4) US9402841B2 (hr)
EP (2) EP3235814B1 (hr)
JP (2) JP6271700B2 (hr)
KR (1) KR102300612B1 (hr)
CN (1) CN105121427B (hr)
AP (1) AP2015008646A0 (hr)
AR (1) AR095198A1 (hr)
AU (1) AU2014249248B2 (hr)
BR (1) BR112015020264B1 (hr)
CA (1) CA2899948C (hr)
CL (1) CL2015002370A1 (hr)
CR (1) CR20150470A (hr)
CY (1) CY1119356T1 (hr)
DK (1) DK2970202T3 (hr)
DO (1) DOP2015000184A (hr)
EA (1) EA028584B1 (hr)
EC (1) ECSP15042779A (hr)
ES (2) ES2624439T3 (hr)
GE (1) GEP201706778B (hr)
HK (2) HK1220183A1 (hr)
HR (1) HRP20170622T1 (hr)
HU (1) HUE032720T2 (hr)
IL (1) IL240353B (hr)
JO (1) JO3377B1 (hr)
LT (1) LT2970202T (hr)
MA (1) MA38391B1 (hr)
ME (1) ME02693B (hr)
MX (1) MX364527B (hr)
MY (1) MY183927A (hr)
PE (1) PE20151889A1 (hr)
PH (1) PH12015502046B1 (hr)
PL (1) PL2970202T3 (hr)
PT (1) PT2970202T (hr)
RS (1) RS55879B1 (hr)
SG (1) SG11201506112QA (hr)
SI (1) SI2970202T1 (hr)
TN (1) TN2015000342A1 (hr)
TW (1) TWI637950B (hr)
UA (1) UA114944C2 (hr)
UY (1) UY35376A (hr)
WO (1) WO2014164558A1 (hr)
ZA (1) ZA201505996B (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3181567T3 (da) 2012-09-10 2019-06-11 Principia Biopharma Inc Pyrazolopyrimidinforbindelser som kinasehæmmere
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
CN104447530A (zh) * 2014-12-11 2015-03-25 苏州欧凯医药技术有限公司 4-甲基-2,6-二羧基吡啶的制备方法
PT3233103T (pt) * 2014-12-18 2021-01-18 Principia Biopharma Inc Tratamento de pênfigo
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
AR107132A1 (es) * 2015-12-24 2018-03-21 Takeda Pharmaceuticals Co Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal
HUE052893T2 (hu) * 2016-01-13 2021-05-28 Acerta Pharma Bv Antifolát és BTK-gátló terápiás kombinációi
CN109071496B (zh) * 2016-03-31 2021-07-30 武田药品有限公司 异喹啉基三唑酮复合物
CA3028169A1 (en) 2016-06-29 2018-01-04 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
EP3827008A1 (en) 2018-07-25 2021-06-02 Novartis AG Nlrp3 inflammasome inhibitors
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
EP3949963A4 (en) * 2019-04-02 2023-01-04 Yonsei University, University-Industry Foundation(UIF). NEW COMPOUND AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF RESPIRATORY DISEASES COMPRISING THIS AS AN ACTIVE PRINCIPLE
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CR20230125A (es) 2020-08-14 2023-05-11 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5733849A (en) * 1996-03-15 1998-03-31 Rohm And Haas Company Halopyridyl triazolinone herbicides and herbicidal use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
MXPA00010150A (es) 1998-04-17 2002-05-14 Parker Hughes Inst Inhibidores de btk y metodos para su identificacion y uso.
KR100876069B1 (ko) * 2000-09-15 2008-12-26 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
CA2433018A1 (en) 2000-12-21 2002-06-27 Joel C. Barrish Thiazolyl inhibitors of tec family tyrosine kinases
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
WO2007087068A2 (en) 2006-01-13 2007-08-02 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
WO2007139967A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
BRPI0713736A2 (pt) 2006-06-20 2014-11-18 Hoffmann La Roche Derivados de tetralina e indano e emprego destes
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PT2526933E (pt) 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
IL295053A (en) 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
ES2462642T3 (es) 2007-12-14 2014-05-26 F. Hoffmann-La Roche Ag Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
WO2009098144A1 (en) 2008-02-05 2009-08-13 F. Hoffmann-La Roche Ag Novel pyridinones and pyridazinones
UA103327C2 (en) 2008-06-24 2013-10-10 Ф. Хоффманн-Ля Рош Аг Substituted pyridin-2-ones and pyridazin-3-ones
BRPI0913879A2 (pt) 2008-07-02 2019-09-24 Hoffmann La Roche fenilpirazinonas como inibidores de quinase
ES2552681T3 (es) 2008-07-15 2015-12-01 F. Hoffmann-La Roche Ag Nuevas fenil-imidazopiridinas y piridazinas
EP2365970B1 (en) 2008-11-12 2018-03-21 Gilead Connecticut, Inc. Pyridazinones and their use as btk inhibitors
WO2010068788A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
WO2010068810A2 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
MX2012013127A (es) 2010-05-13 2012-11-30 Amgen Inc Compuestos heteroariloxiheterociclilo como inhibidores pde10.
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
CA2815131C (en) 2010-10-20 2020-06-09 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as kcnq2/3 modulators
JP2013544321A (ja) 2010-11-10 2013-12-12 エスティーシー． ユーエヌエム ゼロ原子価金属粒子用エアロゾル還元／膨張合成（ａ−ｒｅｓ）
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
ME02693B (me) 2017-10-20
AR095198A1 (es) 2015-09-30
LT2970202T (lt) 2017-06-12
SI2970202T1 (sl) 2017-07-31
JP2016512515A (ja) 2016-04-28
PL2970202T3 (pl) 2017-08-31
EA028584B1 (ru) 2017-12-29
AU2014249248A1 (en) 2015-08-20
JP2018076357A (ja) 2018-05-17
CA2899948C (en) 2021-11-16
PH12015502046A1 (en) 2016-01-18
SG11201506112QA (en) 2015-09-29
EP2970202B1 (en) 2017-02-01
TW201522328A (zh) 2015-06-16
RS55879B1 (sr) 2017-08-31
WO2014164558A1 (en) 2014-10-09
US20140256734A1 (en) 2014-09-11
ZA201505996B (en) 2016-11-30
HK1245256B (zh) 2019-09-27
US20190224190A1 (en) 2019-07-25
US20180015083A1 (en) 2018-01-18
PT2970202T (pt) 2017-05-03
BR112015020264A2 (pt) 2017-07-18
HK1220183A1 (zh) 2017-04-28
CY1119356T1 (el) 2018-02-14
EP3235814B1 (en) 2018-12-12
PH12015502046B1 (en) 2016-01-18
EP2970202A1 (en) 2016-01-20
US10307414B2 (en) 2019-06-04
US9801872B2 (en) 2017-10-31
CA2899948A1 (en) 2014-10-09
EA201591686A1 (ru) 2015-12-30
US9402841B2 (en) 2016-08-02
CR20150470A (es) 2016-01-11
AP2015008646A0 (en) 2015-08-31
KR20150126687A (ko) 2015-11-12
US20160310483A1 (en) 2016-10-27
BR112015020264B1 (pt) 2021-03-02
JP6462842B2 (ja) 2019-01-30
MX364527B (es) 2019-04-30
KR102300612B1 (ko) 2021-09-09
UY35376A (es) 2014-10-31
JO3377B1 (ar) 2019-03-13
IL240353B (en) 2018-11-29
EP3235814A1 (en) 2017-10-25
UA114944C2 (uk) 2017-08-28
ES2714166T3 (es) 2019-05-27
DOP2015000184A (es) 2015-11-30
DK2970202T3 (en) 2017-05-08
PE20151889A1 (es) 2015-12-26
JP6271700B2 (ja) 2018-01-31
MA38391A1 (fr) 2018-01-31
MX2015011533A (es) 2016-02-03
AU2014249248B2 (en) 2017-08-17
NZ710852A (en) 2020-12-18
ES2624439T3 (es) 2017-07-14
GEP201706778B (en) 2017-11-27
CN105121427A (zh) 2015-12-02
CN105121427B (zh) 2018-04-10
ECSP15042779A (es) 2017-08-31
MA38391B1 (fr) 2018-09-28
MY183927A (en) 2021-03-17
TWI637950B (zh) 2018-10-11
TN2015000342A1 (en) 2017-01-03
HUE032720T2 (en) 2017-10-30
CL2015002370A1 (es) 2016-03-11
IL240353A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
HRP20170622T1 (hr) Derivati piridinila i kondenziranog piridinil triazolona
JP2016512515A5 (hr)
JP6114809B2 (ja) ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用
JP5881718B2 (ja) Ｃｘｃｒ４受容体アンタゴニスト
HRP20150173T1 (hr) Oksazolom supstituirani indazoli kao inhibitori pi3-kinaze
US6509361B1 (en) 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
JP2019525941A (ja) ジメトキシフェニル置換インドール化合物
SI3074386T1 (en) New aminopyrimidine derivatives
JP2017530185A5 (hr)
JP2015526441A5 (hr)
JP2017533968A5 (hr)
JP2016525135A (ja) ＢＥＴタンパク質およびポロ様キナーゼの二重阻害薬としての置換されたジヒドロピリド［３，４−ｂ］ピラジノン類
JP2016516043A5 (hr)
JP2016526576A5 (hr)
JP2011500758A5 (hr)
JP2014506599A5 (hr)
JP2013515729A5 (hr)
JP2016523911A5 (hr)
SI3008053T1 (en) PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS
KR20130038420A (ko) 브루톤 티로신 키나아제의 억제제
JP2011522866A5 (hr)
EP2953940A1 (en) Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
WO2016210037A1 (en) Heteroaryl substituted aminopyridine compounds
JP2021507918A (ja) Ｔｌｒ阻害剤として有効なアミノインドール化合物
JP2020529433A (ja) Ｔｌｒ７／８／９の阻害剤として有用な置換インドール化合物